Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
Neurocrine(NBIX) Seeking Alpha·2024-12-18 15:11Neurocrine Biosciences (NASDAQ: NBIX ) remains a key player in the biopharmaceutical sector. Its main focus is on neurological, neuroendocrine, and neuropsychiatric treatment. Since my last analysis in July 2024, NBIX’s Ingrezza, its flagship product, isMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in B ...